Top Markets
#1 PulseChain PulseChain +45.01%
#2 RedStone RedStone +16.75%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.64%
#4 Meteora Meteora +9.03%
#5 SkyAI SkyAI +8.73%
#6 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +8.09%
#7 Unit Pump Unit Pump +7.79%
#8 Pump.fun Pump.fun +7.79%
#9 Lighter Lighter +7.66%
#10 Lista DAO Lista DAO +7.22%
Coin of the day
PulseChain PulseChain
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Clasificación en acciones #28046
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Precio por acción
$0.55
Última sincronización: 2025-02-11
Capitalización bursátil
$28.90M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Marinus Pharmaceuticals, Inc. (MRNS)

Categoría

Healthcare
Margen Operativo de Marinus Pharmaceuticals, Inc. (MRNS)
Margen Operativo al August 2026 TTM: -424.30%
Según los informes financieros más recientes y el precio de las acciones de Marinus Pharmaceuticals, Inc., el margen operativo actual (TTM) es -424.30%. Al final de 2022, el margen operativo era -442.69%.
Historial de Margen Operativo de Marinus Pharmaceuticals, Inc. desde 2012 hasta 2026
Margen Operativo al final de cada año
Año Margen Operativo Cambiar
2026 (TTM) -424.30% 0.00%
2023 -424.30% -4.15%
2022 -442.69% -29.92%
2021 -631.68% -84.03%
2020 -3,954.42% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% -100.00%
2012 -1,430.66% 0.00%
Margen Operativo de empresas similares o competidoras
Empresa Margen Operativo Diferencia de Margen Operativo País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -100.09%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -99.65%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -100.07%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -100.06%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.